Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Nov 2018 11:17 AM
RNS
Amendment to Preclinical Efficacy Announcement
30 Nov 2018 07:45 AM
RNS
Preclinical Efficacy for Immunotherapy Combination
15 Nov 2018 10:24 AM
RNS
Preclinical Data for SRA737 in Ovarian Cancer
14 Nov 2018 07:00 AM
RNS
AGM NOTICE
13 Nov 2018 07:00 AM
RNS
Directorate Change
08 Nov 2018 12:28 PM
RNS
Sierra Oncology Q3 2018 Results
26 Oct 2018 07:00 AM
RNS
Completion of Placing
01 Oct 2018 07:00 AM
RNS
FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
27 Sep 2018 01:03 PM
RNS
Notice of Results
26 Sep 2018 07:00 AM
RNS
TYK2/JAK1 selected for certain cancers
11 Sep 2018 07:00 AM
RNS
Pre-Close Trading Statement
10 Sep 2018 07:00 AM
RNS
Selection of TYK2/JAK1 for autoimmune diseases
09 Aug 2018 01:15 PM
RNS
Sareum notes Sierra Oncology Q2 2018 Results
11 Jul 2018 09:38 AM
RNS
Notification of PCA Shareholding
15 Jun 2018 07:00 AM
RNS
Advisers
31 May 2018 07:00 AM
RNS
Sareum regains rights to Aurora+FLT3 inhibitors
10 May 2018 12:21 PM
RNS
SRA737 trial update in Sierra Oncology Q1 Results
24 Apr 2018 07:00 AM
RNS
Sareum to Present at BioTrinity 2018 in London
17 Apr 2018 12:45 PM
RNS
AACR 2018 Update
15 Mar 2018 07:00 AM
RNS
Late-breaker abstract for SRA737 accepted for AACR
13 Mar 2018 07:00 AM
RNS
Interim Results
27 Feb 2018 12:50 PM
RNS
Sierra Oncology expands SRA737 development program
22 Feb 2018 07:00 AM
RNS
Preclinical synergy of sra737 and PARP inhibitor
13 Feb 2018 07:00 AM
RNS
Notice of Interim Results
20 Dec 2017 11:00 AM
RNS
Issue of Options
19 Dec 2017 07:00 AM
RNS
Patent Grants in Japan & China for TYK2 Inhibitors
14 Dec 2017 11:01 AM
RNS
Result of AGM
14 Dec 2017 07:00 AM
RNS
AGM Statement
20 Nov 2017 07:00 AM
RNS
Notice of AGM and Annual Report & Accounts
14 Nov 2017 12:05 PM
RNS
Placing
31 Oct 2017 07:00 AM
RNS
Sierra Reports Preclinical Data for Chk1 Inhibitor
19 Oct 2017 07:00 AM
RNS
Final Results
09 Oct 2017 12:00 PM
RNS
Sierra Oncology host KOL Meeting on 12 Oct in NY
18 Sep 2017 12:00 PM
RNS
Sierra Oncology to host call on Chk1 inhibitor
22 Aug 2017 07:00 AM
RNS
Pre-Close Trading Statement
19 Jun 2017 07:00 AM
RNS
Sareum to Present at the ICCS 2017
05 Jun 2017 12:13 PM
RNS
Chk1 Clinical Trials Update
31 May 2017 07:00 AM
RNS
Sierra Oncology Granted US and EU Patents
25 May 2017 07:00 AM
RNS
Sierra Oncology to Present at ASCO Annual Meeting
09 May 2017 07:00 AM
RNS
Sareum to Present at BioTrinity 2017
09 Mar 2017 07:00 AM
RNS
Director Shareholding
20 Feb 2017 07:00 AM
RNS
Half-year Results
09 Feb 2017 07:00 AM
RNS
Notice of Interim Results
09 Jan 2017 12:05 PM
RNS
Milestone Payment from Chk1 Licence Agreement
22 Dec 2016 09:47 AM
RNS
Result of General Meeting
15 Dec 2016 11:38 AM
RNS
Result of AGM
06 Dec 2016 07:00 AM
RNS
Directors' Remuneration & General Meeting
29 Nov 2016 07:00 AM
RNS
Sareum to Present at AACR-NCI-EORTC Conference
21 Nov 2016 07:00 AM
RNS
Notice of AGM
02 Nov 2016 07:00 AM
RNS
Final Results

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

SAR share price listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings